Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and Apatinib with Chemotherapy in Resectable Intrahepatic Cholangiocarcinoma
NCT06280508Phase 2Recruiting
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2027
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab, Rivoceranib in intrahepatic cholangiocarcinoma (ICC), sponsored by Sun Yat-sen Memorial Hospital. Started Mar 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranib
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06280508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06280508.